Herts Healthcare Accelerator
The Herts Healthcare Accelerator programme was designed to support the development of healthcare, biotech, and MedTech innovations, including new potential products, services, or allied technologies, which ran from March to September 2023.
Successful applicants were able to access a tailored package of support worth around £15,000 per company from a range of industry and academic experts to help them deliver their proposed idea, which included:
- funding and technical support
- commercial and creative consultancy
- 1-2-1 business mentoring.
Hertfordshire: a regional centre of healthcare innovation
Hertfordshire has a rich history of pharmaceutical, healthcare, and biotechnology innovation. Within 10 miles of our campuses there are several world-leading companies including Roche, Eisai, and GSK as well as the Stevenage Science Park and the Cell and Gene Therapy Catapult, which are designed to encourage innovation in biotech and healthcare. The sector as a whole is of strategic importance to the region, as noted in a recent sector report from the Hertfordshire LEP.
Partnering with Herts to drive your healthcare venture forward
Herts' Healthcare Accelerator aimed to provide businesses with access to a range of Herts experts from across various fields including life sciences, technology, design, business, and law to enable the development of innovations and early-stage research and development (R&D) that would benefit from a multi-disciplinary approach.
Herts has a strong portfolio of research, development, and innovation in this field, including topical drug delivery, toxicology of medicines, diagnostic tools to support the safe use of medicines, proteins involved in pancreatic cancer, improvement of older people’s health outcomes and care, robotics applied to prosthetic developments, and more.
How did businesses benefit?
All selected innovators were supported to develop, test, and/or refine a Minimum Viable Product (MVP), new product, service and/or technology as well as their business models and commercialisation plans.